Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.

Article Details

Citation

Copy to clipboard

Cherkasov A, Ban F, Li Y, Fallahi M, Hammond GL

Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.

J Med Chem. 2006 Dec 14;49(25):7466-78.

PubMed ID

17149875 [ View in PubMed

]

Abstract

A combination of protein-ligand docking and ligand-based QSAR approaches has been elaborated, aiming to speed-up the process of virtual screening. In particular, this approach utilizes docking scores generated for already processed compounds to build predictive QSAR models that, in turn, assess hypothetical target binding affinities for yet undocked entries. The "progressive docking" has been tested on drug-like substances from the NCI database that have been docked into several unrelated targets, including human sex hormone binding globulin (SHBG), carbonic anhydrase, corticosteroid-binding globulin, SARS 3C-like protease, and HIV1 reverse transcriptase. We demonstrate that progressive docking can reduce the amount of computations 1.2- to 2.6-fold (when compared to traditional docking), while maintaining 80-99% hit recovery rates. This progressive-docking procedure, therefore, substantially accelerates high throughput screening, especially when using high accuracy (slower) docking approaches and large-sized datasets, and has allowed us to identify several novel potent nonsteroidal SHBG ligands.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Estradiol	Sex hormone-binding globulin	IC 50 (nM)	50	N/A	N/A	Details
Testosterone	Sex hormone-binding globulin	IC 50 (nM)	14	N/A	N/A	Details